JP2004517049A5 - - Google Patents

Download PDF

Info

Publication number
JP2004517049A5
JP2004517049A5 JP2002525102A JP2002525102A JP2004517049A5 JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5 JP 2002525102 A JP2002525102 A JP 2002525102A JP 2002525102 A JP2002525102 A JP 2002525102A JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5
Authority
JP
Japan
Prior art keywords
solvate
salt
functional derivative
physiologically functional
ylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002525102A
Other languages
English (en)
Other versions
JP2004517049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/026423 external-priority patent/WO2002020479A1/en
Publication of JP2004517049A publication Critical patent/JP2004517049A/ja
Publication of JP2004517049A5 publication Critical patent/JP2004517049A5/ja
Pending legal-status Critical Current

Links

Claims (6)

  1. 式I：
    Figure 2004517049
    ［式中、
    R1は水素又はハロゲンであり；
    R2は水素、ヒドロキシ又はメトキシであり；
    R3は水素又はC1-C6分枝アルキルであり；
    R4は4'-CH2-SO2NHCH3、4'-NHSO2CH3、
    Figure 2004517049
    又は3'-SO2NH2からなる群より選択され；
    R5は水素であり；及び
    XはN又はCHである］
    の化合物又はその塩、溶媒和物もしくは生理学的機能性誘導体。
  2. {4-[(2Z)-2-(4-クロロ-5-ヒドロキシ-6-イソプロピル-2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)ヒドラジノ]フェニル}-N-メチルメタンスルホンアミド；
    N-(4-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}フェニル)メタンスルホンアミド；
    4-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}-N-(2-ピリジニル)ベンゼンスルホンアミド；
    N-(5-メチル-1,3,4-チアジアゾール-2-イル)-4-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}ベンゼンスルホンアミド；3-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}ベンゼンスルホンアミドからなる群から選択される化合物；及びその塩、溶媒和物又は生理学的機能性誘導体。
  3. 治療的有効量の請求項１もしくは２記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体、及び１以上の製薬上許容されるキャリアー、希釈剤、及び添加剤を含有する医薬組成物。
  4. 治療に使用する、請求項１もしくは２記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体。
  5. 不適切なＴｒｋＡ活性が介在する障害の治療に使用するための医薬の調製における、請求項１もしくは２記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体の使用。
  6. 不適切な分裂促進因子活性化型キナーゼ活性が介在する障害の治療に使用するための医薬の調製における、請求項１もしくは２記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体の使用。
JP2002525102A 2000-09-01 2001-08-23 チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 Pending JP2004517049A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23005000P 2000-09-01 2000-09-01
PCT/US2001/026423 WO2002020479A1 (en) 2000-09-01 2001-08-23 Substituted oxindole derivatives as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2004517049A JP2004517049A (ja) 2004-06-10
JP2004517049A5 true JP2004517049A5 (ja) 2005-04-07

Family

ID=22863755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002525102A Pending JP2004517049A (ja) 2000-09-01 2001-08-23 チロシンキナーゼ阻害剤としての置換オキシインドール誘導体

Country Status (5)

Country Link
US (2) US7071217B2 (ja)
EP (1) EP1339680A1 (ja)
JP (1) JP2004517049A (ja)
AU (1) AU2001288374A1 (ja)
WO (1) WO2002020479A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517049A (ja) * 2000-09-01 2004-06-10 グラクソ　グループ　リミテッド チロシンキナーゼ阻害剤としての置換オキシインドール誘導体
US6765012B2 (en) * 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE60335957D1 (de) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
EP1594441B1 (en) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
EP1697384B1 (en) 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
KR20060135060A (ko) 2004-04-07 2006-12-28 리나트 뉴로사이언스 코퍼레이션 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
BRPI0516883A (pt) * 2004-10-25 2008-09-23 Ligand Pharm Inc compostos e métodos para modulação da atividade de trombopoietina
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
JP5182088B2 (ja) 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
EP2044084B1 (en) 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
AU2008265104B2 (en) * 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
CA2703106C (en) 2007-10-24 2015-12-01 Astellas Pharma Inc. Azolecarboxamide derivatives as trka inhibitors
US8426673B2 (en) 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
WO2023212596A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6269086B1 (en) * 1998-02-27 2001-07-31 Legerity, Inc. Arrangement and method for selectable time/frequency division multiplex communication
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6624171B1 (en) * 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6492398B1 (en) * 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6498176B1 (en) * 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
US6620818B1 (en) * 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
JP2004517049A (ja) * 2000-09-01 2004-06-10 グラクソ　グループ　リミテッド チロシンキナーゼ阻害剤としての置換オキシインドール誘導体
WO2003027111A1 (en) 2001-09-27 2003-04-03 Smithkline Beecham Corporation Chemical compounds

Similar Documents

Publication Publication Date Title
JP2004517049A5 (ja)
JP2004517087A5 (ja)
JP6021805B2 (ja) 腫瘍治療剤
JP2005508337A5 (ja)
RU2004117887A (ru) Ариланилиновые агонисты бета2 адренергических рецепторов
RU2008112221A (ru) Соединения ряда изоиндолимидов, их композиции и способы применения
JP2005523922A5 (ja)
JP2005509024A5 (ja)
JP2006509749A5 (ja)
JP2014502979A5 (ja)
JP2008534453A5 (ja)
JP2009501745A5 (ja)
JP2010501478A5 (ja)
AU2016252860B2 (en) Compositions and methods for inhibiting kinases
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
RU2007120710A (ru) Способ лечения рака и/или лейкоза и применяемая в нем фармацевтическая композиция
JP2020512337A5 (ja)
AU2011227398A1 (en) Modulators of Hec1 activity and methods therefor
TW201912153A (zh) 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
CA2635093A1 (en) Derivatives of sulindac, use thereof and preparation thereof
JPWO2020038415A5 (ja)
JP2008508350A5 (ja)
RU2004119963A (ru) Ингибиторы вич интегразы
JP2006516626A5 (ja)
JP2007501284A5 (ja)